These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
612 related articles for article (PubMed ID: 27451030)
1. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030 [TBL] [Abstract][Full Text] [Related]
2. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Smits MM; Fluitman KS; Herrema H; Davids M; Kramer MHH; Groen AK; Belzer C; de Vos WM; Cahen DL; Nieuwdorp M; van Raalte DH Diabetes Metab; 2021 Sep; 47(5):101223. PubMed ID: 33429063 [TBL] [Abstract][Full Text] [Related]
3. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794 [TBL] [Abstract][Full Text] [Related]
4. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916 [TBL] [Abstract][Full Text] [Related]
5. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981 [TBL] [Abstract][Full Text] [Related]
6. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201 [TBL] [Abstract][Full Text] [Related]
7. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653 [TBL] [Abstract][Full Text] [Related]
8. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Tonneijck L; Smits MM; Muskiet MH; Hoekstra T; Kramer MH; Danser AH; Ter Wee PM; Diamant M; Joles JA; van Raalte DH Diabetes Care; 2016 Nov; 39(11):2042-2050. PubMed ID: 27585605 [TBL] [Abstract][Full Text] [Related]
9. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pieters-van den Bos IC; Vendrik KE; Hoekstra T; Bruno MJ; Diamant M; van Raalte DH; Cahen DL Diabetes Care; 2017 Mar; 40(3):301-308. PubMed ID: 27998910 [TBL] [Abstract][Full Text] [Related]
10. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307 [TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853 [TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Bailey TS; Takács R; Tinahones FJ; Rao PV; Tsoukas GM; Thomsen AB; Kaltoft MS; Maislos M Diabetes Obes Metab; 2016 Dec; 18(12):1191-1198. PubMed ID: 27381275 [TBL] [Abstract][Full Text] [Related]
16. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Pieters IC; Cahen DL; Diamant M; van Raalte DH BMJ Open; 2015 Nov; 5(11):e009579. PubMed ID: 26586327 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW; Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436 [TBL] [Abstract][Full Text] [Related]
19. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]